Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2020-10-06 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - IMU 6 pages 30.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number and type of securities to be issued, the issue price, underwriting arrangements, and compliance with ASX listing rules. There are no financial statements or detailed financial performance data included, and the document is focused on informing about the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other filing types.
2020-10-06 English
Appendix 2A 15 pages 388.2KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and the nature of the issue. The document is a formal announcement related to capital markets activity, specifically the quotation of new securities following a transaction previously announced in an Appendix 3B. This type of document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital structure changes and securities quotation. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2020-10-06 English
Imugene Immunotherapy Combination Patent Granted in US 2 pages 131.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 2 October 2020, regarding the granting of a core US patent for their immunotherapy combination. It discusses the patent details, its significance, and quotes the CEO. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a regulatory announcement about intellectual property rights and company milestones, not a financial report or earnings release. It is also not a report publication announcement since it contains substantive information about the patent grant. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-10-01 English
Imugene appoints Dr Rita Laeufle as Chief Medical Officer 2 pages 141.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement about the appointment of a new Chief Medical Officer at Imugene Limited. It focuses on management changes and does not contain financial data, regulatory filings, or report announcements. The content is about a senior management appointment, which fits the category of Board/Management Information (MANG). The document length is 4524 characters, which is consistent with a typical announcement rather than a full report. There is no indication of financial results, voting results, or other report types.
2020-09-29 English
Letter to IMUOA & IMUOB Option Share Holders 3 pages 939.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notice and form for exercising stock options (IMUOA and IMUOB) by shareholders of Imugene Limited. It includes instructions on how to exercise options, payment methods, and contact details for the share registry. There is no financial performance data, no discussion of financial results, no management commentary, no voting results, no legal proceedings, and no mention of any report publication. The content is focused on the capital raising activity through option exercise, which is a financing event. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8309 characters) supports it being a full notice rather than a brief announcement or a report publication announcement.
2020-09-29 English
Proposed issue of Securities - IMU 6 pages 30.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number of securities to be issued, the issue price, underwriting arrangements, and compliance with ASX listing rules. There is no financial data or performance analysis, nor is it a report or transcript. The content fits the category of a capital or financing update, specifically about a placement or other type of securities issue. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2020-09-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.